AZN.L - AstraZeneca PLC
NEXT EARNINGS:
Apr 29, 2026
EPS Est: $2.53
|
Rev Est: $14.7B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Market Cap:
237.60B
Volume:
6,749,803
Avg Volume:
2,455,954
52 Week Range:
9573.505-15732
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.19
Last Dividend:
$236.20
Exchange:
LSE
Country:
GB
Employees:
94,300
IPO Date:
1993-05-21
EPS (TTM):
6.60
P/E Ratio:
28.13
Revenue (TTM):
58.74B
Total Assets:
114.07B
Total Debt:
29.62B
Cash & Equiv:
5.71B
Rev Growth (5Y):
14.9%
EPS Growth (5Y):
20.7%
FCF Growth (5Y):
31.6%
ROCE:
16.9%
Debt/Equity:
0.61
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-10 | $1.55 | $1.53 | +1.3% | $11.5B | $11.3B | +1.6% |
| 2025-11-06 | $1.81 | $1.74 | +4.0% | $11.3B | $11.2B | +0.4% |
| 2025-07-29 | $1.63 | $1.63 | 0.0% | $10.9B | $10.6B | +2.7% |
| 2025-04-29 | $1.87 | $1.68 | +11.3% | $10.5B | $10.4B | +1.0% |
| 2025-02-06 | $1.69 | $1.67 | +1.2% | $11.9B | $11.5B | +3.6% |
| 2024-11-12 | $1.65 | $1.49 | +10.7% | $10.3B | $10.4B | -0.1% |
| 2024-07-25 | $1.98 | $1.96 | +1.0% | $10.2B | $9.8B | +4.2% |
| 2024-04-25 | $2.06 | $1.91 | +7.9% | $10.1B | $9.4B | +7.6% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 58.74B | 52.94B | 46.58B | 44.25B | 37.11B | 29.27B | 24.50B | 20.99B | 23.45B | 20.92B | 23.93B | 25.89B |
| Net Income | 10.22B | 6.89B | 6.06B | 3.28B | 109.85M | 3.39B | 1.34B | 2.05B | 3.13B | 3.18B | 2.74B | 1.20B |
| EPS | 6.60 | 4.44 | 3.91 | 2.12 | 0.08 | 2.58 | 1.03 | 1.62 | 2.47 | 2.52 | 2.16 | 0.96 |
| Total Assets | 114.07B | 104.03B | 101.12B | 96.48B | 105.36B | 66.73B | 61.38B | 60.65B | 63.35B | 62.53B | 60.06B | 58.59B |
| Total Debt | 29.62B | 30.11B | 28.41B | 29.14B | 30.69B | 20.38B | 18.23B | 19.11B | 17.81B | 16.81B | 15.05B | 10.84B |
| Cash & Equivalents | 5.71B | 5.48B | 5.79B | 6.17B | 6.30B | 7.79B | 5.37B | 4.75B | 3.32B | 4.93B | 6.13B | 6.25B |
| Operating Cash Flow | 14.57B | 11.86B | 10.35B | 9.81B | 5.96B | 4.80B | 2.97B | 2.62B | 3.58B | 4.14B | 3.32B | 7.06B |
| Free Cash Flow | 8.67B | 7.28B | 6.57B | 7.24B | 3.76B | 2.19B | 509.00M | 1.25B | 1.96B | 1.83B | 536.00M | 4.31B |
| FCF per Share | 5.59 | 4.69 | 4.20 | 4.68 | 2.65 | 1.67 | 0.39 | 0.98 | 1.55 | 1.45 | 0.42 | 3.41 |
| Book Value | 48.67B | 40.79B | 39.14B | 37.04B | 39.27B | 15.62B | 13.13B | 12.47B | 14.96B | 14.85B | 18.49B | 19.63B |
| Cash & ST Investments | 5.74B | 5.65B | 5.91B | 6.24B | 6.37B | 7.95B | 6.22B | 5.59B | 4.55B | 5.81B | 6.88B | 6.38B |
| ROC Equity | 0.21 | 0.17 | 0.15 | 0.09 | 0.00 | 0.22 | 0.10 | 0.16 | 0.21 | 0.21 | 0.15 | 0.06 |